To understand the USP22-dependent signaling pathways underlying its oncogenic properties, we performed transcriptome-wide analyses in murine HER2+-BC tumors and HCC1954 cells by mRNA-sequencing (mRNA-seq) following genetic Usp22 deletion or siRNA-mediated USP22 depletion, respectively. Here, ERBB2 is linked to breast cancer.